Holen Sie sich die Stockscreener-App
65.36
1.22%
-0.81
Handel nachbörslich:
64.99
-0.37
-0.57%
Schlusskurs vom Vortag:
$66.17
Offen:
$64.41
24-Stunden-Volumen:
3.24M
Relative Volume:
1.20
Marktkapitalisierung:
$12.67B
Einnahmen:
$353.78M
Nettoeinkommen (Verlust:
$-805.69M
KGV:
-15.61
EPS:
-4.1869
Netto-Cashflow:
$-597.61M
1W Leistung:
-1.68%
1M Leistung:
-3.95%
6M Leistung:
+22.44%
1J Leistung:
+102.79%
1-Tages-Spanne:
$63.62
$66.06
1-Wochen-Bereich:
$62.77
$67.20
52-Wochen-Spanne:
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
65.36 | 12.83B | 353.78M | -805.69M | -597.61M | -4.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 117.06B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.86 | 80.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
717.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.66 | 42.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.12 | 32.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating - Bitget
(BBIO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
GW&K Investment Management LLC Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma Talks Atrubie Momentum, Phase 3 Wins as Tafamidis IP Trial Looms - Yahoo Finance
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference - Bitget
BridgeBio Pharma to Present Phase 3 FORTIFY Trial Data on LGMD2I/R9 Therapy at 2026 MDA Conference - geneonline.com
BridgeBio to present LGMD2I/R9 trial data at MDA conference By Investing.com - Investing.com Australia
[144] BridgeBio Pharma, Inc. SEC Filing - Stock Titan
BridgeBio to present LGMD2I/R9 trial data at MDA conference - Investing.com Nigeria
TD Asset Management Inc Purchases Shares of 88,950 BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Latest Stock News & Headlines - Yahoo Finance
BridgeBio Pharma to Present New Data on BBP-418 for LGMD2I/R9 at MDA Conference - Quiver Quantitative
BridgeBio muscular dystrophy trial hits key goals in Phase 3 study - Stock Titan
Aisling Capital Management LP Has $316.29 Million Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma Director Sells Shares - TradingView
BridgeBio (BBIO) director sells 25,484 shares after option exercise - Stock Titan
BBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rafferty Asset Management LLC Sells 44,792 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success - Bitget
Intech Investment Management Trims BridgeBio Pharma Stake - National Today
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Unpacking a 50.49% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Intech Investment Management LLC Sells 19,826 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Is BridgeBio Pharma (BBIO) Attractive After Recent Pullback And Late Stage Pipeline Progress? - Yahoo Finance
Okabena Investment Services Inc. Makes New $816,000 Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Monashee Investment Management LLC Lowers Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
ETFs investiert in BridgeBio Pharma, Inc.-Aktien - TradingView
BridgeBio Pharma Sees Pivotal Shift As Late Stage Success Meets Attruby Sales - simplywall.st
Fox Run Management L.L.C. Reduces Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Insider Sell: Maricel Apuli Sells 2,000 Shares of BridgeBio Phar - GuruFocus
What BridgeBio Pharma (BBIO)'s Surging 2025 Revenue and Growing Losses Means For Shareholders - simplywall.st
BridgeBio (BBIO) CAO sells 2,000 shares in Rule 10b5-1 trade - Stock Titan
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), BridgeBio Pharma (BBIO) and Establishment Labs Holdings (ESTA) - The Globe and Mail
BridgeBio Pharma Earnings Call Signals Profitable Pivot - TipRanks
BridgeBio Pharma (BBIO) Analyst Rating Update: Oppenheimer Lowers Price Target | BBIO Stock News - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Trading Down 6.7% on Disappointing Earnings - MarketBeat
BridgeBio Pharma (BBIO): Today's Analyst Rating Update | BBIO St - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $95.00 at Truist Financial - MarketBeat
Oppenheimer Issues Pessimistic Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
BridgeBio Pharma (BBIO) Receives Analyst Rating and Price Target Update | BBIO Stock News - GuruFocus
Morgan Stanley Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
BridgeBio Pharma (BBIO): Evercore ISI Group Raises Price Target to $125 | BBIO Stock News - GuruFocus
Oppenheimer Adjusts Price Target on BridgeBio Pharma to $81 From $83, Maintains Outperform Rating - marketscreener.com
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q4 2025 Earnings Call Transcript - Insider Monkey
BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside - TipRanks
BridgeBio Pharma Reports Narrower Net Loss For Q4, Revenue Zooms On Attruby Sales - RTTNews
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: St - GuruFocus
BridgeBio Pharma earnings missed by $0.28, revenue topped estimates - Investing.com Australia
Decoding BridgeBio Pharma Inc (BBIO): A Strategic SWOT Insight - GuruFocus
BridgeBio Pharma (BBIO) Projects Strong Cash Flow by 2028 - GuruFocus
BridgeBio Pharma, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
2.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):